Q2 2025 Earnings Call Transcript August 4, 2025 Axsome Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.92 ...

Axsome Therapeutics AXSM incurred an adjusted loss of 97 cents per share in the second quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $1.00. The company had incurred a loss ...

Axsome Therapeutics reported quarterly losses of 47 cents per share compared to analyst consensus estimate of losses of $1.07 per share. The company reported quarterly sales of $150.04 million which ...

Axsome Therapeutics Inc (AXSM) reports a 72% year-over-year revenue increase, driven by strong product sales and strategic ...

Double-digit prescription gains for its commercial drugs, major coverage wins, and the early launch of a new migraine therapy were the most significant highlights. Despite substantial progress, the ...

Key Points Shopify's moat and vast runway for growth make its prospects highly attractive. Axsome Therapeutics has a robust late-stage pipeline that should lead to important approvals.10 stocks we ...

AUVELITY is a prescription oral medicine used to treat adults with major depressive disorder (MDD). It is not known if AUVELITY is safe and effective for use in children.

AUVELITY is a novel, oral, NMDA receptor antagonist with multimodal activity approved for the treatment of MDD in adults. AUVELITY is a proprietary extended-release oral tablet containing ...

AXSM stock rises 20% as it settles Auvelity patent litigation with Teva, protecting the drug's exclusivity in the United States at least until Sept. 30, 2038.